BioTime Inc (BTX):企業のM&A・提携動向(医療機器分野)

【英語タイトル】BioTime Inc (BTX) - Medical Equipment - Deals and Alliances Profile

GlobalDataが出版した調査資料(GDME225D)・商品コード:GDME225D
・発行会社(調査会社):GlobalData
・発行日:2017年2月14日
・ページ数:44
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
BioTime Inc (BioTime) is a biotechnology company with focus on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. The company is also developing Renevia to facilitate cell transplantation; AST-VAC1 autologous (patient-specific) cancer vaccine; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); AST-OPC1 for spinal cord injury rehabilitation; HyStem hydrogel products; and mobile health software products. The company’s products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. The company’s products are developed on its pluripotent stem technology based on induced pluripotent stem (iPS) cells and human embryonic stem (hES) cells. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.

BioTime Inc (BTX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
BioTime Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
BioTime Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
BioTime Inc, Medical Equipment, Deal Details 11
Venture Financing 11
LifeMap Solutions Raises US$5 Million In Seed Financing 11
Partnerships 11
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 11
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 12
OncoCyte Expands Co-Development Agreement with Wistar Institute 13
BioTime Enters Into Distribution Agreement With USCN Life Science 13
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 14
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15
Biotime Amends Licensing Agreement With University of Utah 16
BioTime Enters Into Option Licensing Agreement With USCN Life Science 17
Equity Offering 18
OncoCyte Raises USD3.2 Million in Private Placement of Units 18
OncoCyte Raises USD7.3 Million in Private Placement of Units 19
BioTime Raises USD5 Million in Private Placement of Shares 20
OncoCyte Raises USD3.3 Million in Private Placement of Shares 21
BioTime Completes Private Placement Of Shares For US$6.4 Million 22
BioTime Announces Public Offering Of Shares For Up To US$15 Million 23
BioTime Completes Public Offering Of Shares For US$3.5 Million 23
BioTime Completes Private Placement Of Units For US$9 Million 24
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 25
BioTime Announces Private Placement Of Common Stock 27
BioTime Completes Private Placement For US$3.6 Million 27
Acquisition 28
OrthoCyte Completes Acquisition Of Glycosan BioSystems 28
BioTime Inc – Key Competitors 31
Key Employees 32
Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 35
Financial Announcements 35
Nov 03, 2016: BioTime Reports Third Quarter Results and Recent Clinical Progress 35
Aug 09, 2016: BioTime Reports Second Quarter Results and Recent Corporate Accomplishments 37
May 10, 2016: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 39
Corporate Communications 42
Feb 07, 2017: BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel 42
Oct 31, 2016: BioTime Appoints Industry Veteran Jim Knight as Senior Vice President, Head of Corporate Development 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
BioTime Inc, Medical Equipment, Key Facts, 2015 1
BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
BioTime Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
BioTime Inc, Deals By Market, 2011 to YTD 2017 9
BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
LifeMap Solutions Raises US$5 Million In Seed Financing 11
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 11
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 12
OncoCyte Expands Co-Development Agreement with Wistar Institute 13
BioTime Enters Into Distribution Agreement With USCN Life Science 13
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 14
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15
Biotime Amends Licensing Agreement With University of Utah 16
BioTime Enters Into Option Licensing Agreement With USCN Life Science 17
OncoCyte Raises USD3.2 Million in Private Placement of Units 18
OncoCyte Raises USD7.3 Million in Private Placement of Units 19
BioTime Raises USD5 Million in Private Placement of Shares 20
OncoCyte Raises USD3.3 Million in Private Placement of Shares 21
BioTime Completes Private Placement Of Shares For US$6.4 Million 22
BioTime Announces Public Offering Of Shares For Up To US$15 Million 23
BioTime Completes Public Offering Of Shares For US$3.5 Million 23
BioTime Completes Private Placement Of Units For US$9 Million 24
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 25
BioTime Announces Private Placement Of Common Stock 27
BioTime Completes Private Placement For US$3.6 Million 27
OrthoCyte Completes Acquisition Of Glycosan BioSystems 28
BioTime Inc, Key Competitors 31
BioTime Inc, Key Employees 32
BioTime Inc, Subsidiaries 33

List of Figures
BioTime Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 1
BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 1
BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 1
BioTime Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 1
BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
BioTime Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 7
BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
BioTime Inc, Medical Equipment, Deals by Market, 2011 to YTD 2017 9

★調査レポート[BioTime Inc (BTX):企業のM&A・提携動向(医療機器分野)] (コード:GDME225D)販売に関する免責事項を必ずご確認ください。
★調査レポート[BioTime Inc (BTX):企業のM&A・提携動向(医療機器分野)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆